One To Watch

Disc Medicine

A clinical-stage biopharmaceutical company focused on therapies for serious hematologic diseases, including rare heme biosynthesis disorders and disorders of iron homeostasis. Its pipeline is built around biologic control points that regulate hemoglobin and iron availability.

Company Overview

Disc Medicine develops investigational medicines intended to address disease biology in hematology rather than symptom control alone. The company’s lead programs target heme biosynthesis and iron regulation pathways across rare genetic disorders and more common anemias of chronic disease.

Headquarters and Global Presence

Disc Medicine is based in Watertown, Massachusetts, and runs multinational clinical development programs across North America and other regions through established trial networks.

Founding and History

Disc Medicine is publicly traded on Nasdaq (ticker: IRON). Over the past several years it has advanced a portfolio spanning one late-stage small-molecule program and multiple antibody programs in mid-stage development.

Therapy Areas and Focus

Disc is focused on hematology, with emphasis on:

Rare heme biosynthesis disorders (notably protoporphyria)
Anemias driven by iron restriction and elevated hepcidin (including inflammatory and chronic disease settings)
Iron overload phenotypes where iron restriction may be beneficial (selected indications)
Myeloproliferative diseases with high unmet need and anemia or erythrocytosis components

Technology Platforms and Modalities

Disc’s pipeline uses two primary modalities:

Small-molecule pathway modulation in heme biology
Monoclonal antibodies targeting regulators of hepcidin and iron handling (including HJV and TMPRSS6)

Programs and Clinical Pipeline

Bitopertin (GlyT1 inhibitor; heme biosynthesis modulator)

Erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP): Phase III (ongoing APOLLO study)
Diamond-Blackfan anemia: investigator-initiated study (NIH)

DISC-0974 (anti-HJV monoclonal antibody; hepcidin suppression to increase iron availability)

Anemia of myelofibrosis (MF): Phase II
Anemia of inflammatory bowel disease (IBD): Phase II
Anemia of non-dialysis-dependent chronic kidney disease (CKD): Phase II

DISC-0998 (extended half-life anti-HJV antibody; hepcidin suppression)

Anemia associated with inflammatory diseases: early clinical stage (program disclosed; stage varies by indication)

DISC-3405 (anti-TMPRSS6 monoclonal antibody; hepcidin induction to restrict iron)

Polycythemia vera (PV): Phase II
Sickle cell disease (SCD): Phase I b

Strategic Partnerships

Disc has sourced parts of its pipeline through licensing and in-licensing arrangements and runs partner-supported development and manufacturing planning typical for clinical-stage hematology companies.

FAQ Section

Disc focuses on hematology programs that modulate heme biosynthesis and iron homeostasis. The unifying theme is targeting biologic regulators that control iron availability and hemoglobin-related pathways to address disease drivers across distinct blood disorders.

Disc is focused on hematologic diseases, spanning rare genetic disorders such as EPP/XLP and broader anemia settings linked to hepcidin biology (eg, inflammatory disease and chronic kidney disease), as well as selected myeloproliferative and hemoglobinopathy indications.

The disclosed pipeline includes:

Bitopertin in Phase III for EPP/XLP
DISC-0974 (anti-HJV) in Phase II across multiple anemia indications
DISC-3405 (anti-TMPRSS6) in Phase II (PV) and Phase I b (SCD)
DISC-0998 (extended half-life anti-HJV) in earlier-stage development for inflammatory-disease–associated anemia

Most recent items, in reverse chronological order:

February 2026: Disc reported receipt of an FDA Complete Response Letter for the bitopertin NDA for EPP; the agency indicated it wanted results from the ongoing Phase III APOLLO study before making a decision.
January 2026: Disc outlined 2026 milestones, including planned Phase II updates for DISC-0974 (MF anemia) and initial data from DISC-3405 studies (PV and SCD) expected in H2 2026.

Bitopertin is being studied in EPP/XLP, with a Phase III program underway. Following the February 2026 FDA Complete Response Letter for the EPP NDA, the near-term path centers on completing APOLLO and using those results to support a subsequent regulatory decision.

Key upcoming value drivers are:

Bitopertin: Phase III APOLLO topline timing and the dataset’s ability to support approval in EPP
DISC-0974: updated Phase II data in MF-associated anemia and subsequent end-of-Phase II regulatory interactions
DISC-3405: initial Phase II data in PV and Phase I b data in SCD

Disc’s portfolio balances a late-stage rare-disease opportunity (bitopertin in protoporphyria) with platform-style iron-regulation antibodies that could be applied across multiple anemia and iron-restriction settings. The practical test for breadth will be consistency of hemoglobin and iron-related clinical benefits across heterogeneous patient populations and standards of care.

Want to Update your Company's Profile?